BACKGROUND: Evidence suggests that schizophrenia may have a better outcome for individuals living in low- and middle-income countries compared with affluent settings. AIMS: To determine the frequency of symptom and functional remission in out-patients with schizophrenia in different regions of the world. METHOD: Using data from the Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO) study we measured clinical and functional remission in out-patients with schizophrenia in different regions of the world, and examined sociodemographic and clinical factors associated with these outcomes. The 11 078 participants analysed from 37 participating countries were grouped into 6 regions: South Europe, North Europe, Central and Eastern Europe, Latin America, North Africa and Middle East, and East Asia. RESULTS: In total, 66.1% achieved clinical remission during the 3-year follow-up (range: 60.1% in North Europe to 84.4% in East Asia) and 25.4% achieved functional remission (range: 17.8% in North Africa and Middle East to 35.0% in North Europe). Regional differences were not explained by participants' clinical characteristics. Baseline social functioning, being female and previously untreated were consistent predictors of remission across regions. CONCLUSIONS: Clinical outcomes of schizophrenia seem to be worse in Europe compared with other regions. However, functional remission follows a different pattern.
BACKGROUND: Evidence suggests that schizophrenia may have a better outcome for individuals living in low- and middle-income countries compared with affluent settings. AIMS: To determine the frequency of symptom and functional remission in out-patients with schizophrenia in different regions of the world. METHOD: Using data from the Worldwide-SchizophreniaOutpatient Health Outcomes (W-SOHO) study we measured clinical and functional remission in out-patients with schizophrenia in different regions of the world, and examined sociodemographic and clinical factors associated with these outcomes. The 11 078 participants analysed from 37 participating countries were grouped into 6 regions: South Europe, North Europe, Central and Eastern Europe, Latin America, North Africa and Middle East, and East Asia. RESULTS: In total, 66.1% achieved clinical remission during the 3-year follow-up (range: 60.1% in North Europe to 84.4% in East Asia) and 25.4% achieved functional remission (range: 17.8% in North Africa and Middle East to 35.0% in North Europe). Regional differences were not explained by participants' clinical characteristics. Baseline social functioning, being female and previously untreated were consistent predictors of remission across regions. CONCLUSIONS: Clinical outcomes of schizophrenia seem to be worse in Europe compared with other regions. However, functional remission follows a different pattern.
Authors: Eneritz Bengoetxea; Cynthia Z Burton; Brent T Mausbach; Thomas L Patterson; Elizabeth W Twamley Journal: Psychiatry Res Date: 2014-04-13 Impact factor: 3.222
Authors: Helen J Stain; Kolbjørn Brønnick; Wenche T V Hegelstad; Inge Joa; Jan O Johannessen; Johannes Langeveld; Lauren Mawn; Tor K Larsen Journal: Schizophr Bull Date: 2013-11-26 Impact factor: 9.306
Authors: Lauren C Ng; Jessica F Magidson; Rebecca S Hock; John A Joska; Abebaw Fekadu; Charlotte Hanlon; Janina R Galler; Steven A Safren; Christina P C Borba; Gregory L Fricchione; David C Henderson Journal: Acad Psychiatry Date: 2016-03-14
Authors: Max Lam; Chia-Yen Chen; Zhiqiang Li; Alicia R Martin; Julien Bryois; Xixian Ma; Helena Gaspar; Masashi Ikeda; Beben Benyamin; Brielin C Brown; Ruize Liu; Wei Zhou; Lili Guan; Yoichiro Kamatani; Sung-Wan Kim; Michiaki Kubo; Agung A A A Kusumawardhani; Chih-Min Liu; Hong Ma; Sathish Periyasamy; Atsushi Takahashi; Zhida Xu; Hao Yu; Feng Zhu; Wei J Chen; Stephen Faraone; Stephen J Glatt; Lin He; Steven E Hyman; Hai-Gwo Hwu; Steven A McCarroll; Benjamin M Neale; Pamela Sklar; Dieter B Wildenauer; Xin Yu; Dai Zhang; Bryan J Mowry; Jimmy Lee; Peter Holmans; Shuhua Xu; Patrick F Sullivan; Stephan Ripke; Michael C O'Donovan; Mark J Daly; Shengying Qin; Pak Sham; Nakao Iwata; Kyung S Hong; Sibylle G Schwab; Weihua Yue; Ming Tsuang; Jianjun Liu; Xiancang Ma; René S Kahn; Yongyong Shi; Hailiang Huang Journal: Nat Genet Date: 2019-11-18 Impact factor: 38.330